Compare Merck & Co., Inc. (MRK) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Smith & Nephew plc — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while Smith & Nephew plc trades at $27.96 (market cap $11.62B). The key difference: Merck & Co., Inc. is far larger — about 31.3× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.86%). Which is the better fit depends on your goals.
| MRK | SNN | |
|---|---|---|
Market Cap | $363.98B | $11.62B |
Sector | Health | Health |
52-Week High | $156.43 | $38.53 |
52-Week Low | $77.60 | $27.80 |
Enterprise Value | $410.75B | $14.66B |
Dividend Yield | 2.3% | 2.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SNN trades at $27.87, down 3.46% today and near a 52-week low. Technical indicators are bearish, but oversold RSI levels suggest potential for a rebound. Fundamentally, the company shows strong revenue growth to $6.16 billion in 2025 and a net income margin of 10.08%, though recent guidance cuts and CFO departure have weighed on sentiment. A dividend of $0.31 is scheduled for payment in November 2026.
The outlook is cautious due to competitive pressures and execution risks, but valuation metrics like a P/E of 18.96 appear reasonable. Analyst consensus is Hold, with 65% recommending neutrality. Upside depends on improved operational performance and stabilization in key markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
